A new study in JAMA Oncology warns that GLP-1 receptor agonists like Ozempic and Mounjaro may raise the risk of kidney cancer, even though they seem to lower the risk of other cancers
And so that's part of the food that we eat, the environment we're in, what may be happening to our microbiome, all of these sorts of things
Safety, risks & side effects GLP-1 medications carry real risks
By contrast, metformin appears to exert broader effects on pathways directly implicated in AD pathogenesis, including AMPK, insulin, and adipocytokine signaling
In clinical trials, tirzepatide showed higher average weight loss (up to 21% vs ~15%), but the best choice depends on your metabolic profile and how your body responds